SUMMARY Fourteen Parkinsonian patients with fluctuations in therapeutic response to levodopa completed a double-blind, crossover trial ofcontrolled-release levodopa/carbidopa (Sinemet CR4) vs standard Sinemet 25/100 (STD). Significant increases in mean interdose interval and per cent of the waking day spent "on", as well as reductions in the number of daily medication doses and number of "off" episodes were noted. In the double-blind part of the study, relative to open treatment with STD, ten patients rated themselves as improved while taking CR4, whereas only three considered themselves improved with STD. Difficulties using CR4 included an increased "lag-time" to the onset of antiparkinson effect, a tendency to produce increasingly severe dyskinesia late in the day, and a somewhat lessened predictability of motor response. Nonetheless, since the overall level of motor function through the day was equal to or better than that attained with STD, but with fewer medication administrations, Sinemet CR4 should prove a useful antiparkinsonian agent.
required in Parkinson's disease patients with RFs. '-24 We now report the outcome of a double-blind, crossover comparison of one such preparation, Sinemet CR4, vs. standard Sinemet 25/100 (STD).
Methods
After giving informed consent, 19 patients entered and 14 completed the 24 week study. The mean age of the patients completing the study was 58 3, SEM 1 9 years; the mean duration of Parkinson's disease was 11-07, SEM 0 99 years, and the mean duration of RF was 3-78, SEM 0-66 years. All patients had idiopathic Parkinson's disease with disability scores when "off " of at least 2 (mean = 2-86, SEM 0 23) on the Hoehn and Yahr scale. All had an end-of-dose wearingoffpattern of RFs; all but two suffered peak-dose dyskinesia. Four additional patients had end-dose dystonia. Since it was considered preferable to compare formulations with identical carbidopa/levodopa ratios (Sinemet CR4 contains 50 mg carbidopa and 200 mg levodopa), those patients taking Sinemet 10/100 or 25/250 prior to study entry were switched to 25/100 tablets, and the dose was adjusted to optimise performance before actual entry into the study. Six patients were taking anticholinergic agents and six amantadine at study entry (two were taking both). Three patients had been taking bromocriptine, which was discontinued at least 2 weeks prior to study entry. The label dose-titration phase (DT) and a 16-week double-blind phase (DB). Each phase was likewise divided into two periods. During the first DT period (DT1), the dose of STD was adjusted to achieve maximum "on" time with as little "off" time and dyskinesia as possible. This process was repeated for CR4 during the second DT period (DT2). The starting interdose interval for the CR4 formulation was determined by doubling the final interdose interval from DT1. The initial dose was determined by taking the optimum 24- independent, 0% = totally dependent in all ADL).2V ADL, using both the percent scale and ADL portions of the UPDS, were rated by the patients and/or spouses for both the "on" and "off'" conditions. In addition, patients kept diaries 2 days each week, recording time spent ''off," "on," and "on with dyskinesias." At the end of each DB period, the patients were asked to rate their performance as compared with DT1. At the end of DT2, patients were asked to express a preference for the drug taken during DB1 or DB2.
Data analysis was performed using the CLINFO computer facility of the Cornell Clinical Research Center. Comparisons were carried out using paired Student's t-tests and nonparametric statistics where appropriate. more patients dropped out at the end of DT2; two because of excessive dyskinesia, one due to worsened cognitive function, and one due to worsened Parkinsonism despite a marked increase in daily levodopa intake. The side-effect profile of CR4 was identical to that of STD. The patient who was dropped from the study due to worsened cognitive function had been moderately impaired prior to the study and continued to deteriorate thereafter.
In the double-blind portion ofthe study, 10 ofthe 14 patients considered their motor performance during the CR4 DB period to be better than it was during open-label treatment with STD during DTl, three patients considered themselves better when on STD in the DB phase than during DTl, and one could detect no difference (Chi-square p = 0.024). In comparing performance during the two DB periods, 11 patients expressed a preference for the CR4 DB period, one for STD, and two had no preference (Chi-square p = 0-0015). Eleven patients correctly surmised which tablet was the active one in each of the double blind periods, since individual doses of CR4 took longer to "kick in". This effect was evident even though patients with long delays to turn on were given a larger dose of CR4 upon arising in an attempt to have plasma levodopa levels reach "threshold" sooner. The remaining four patients could not distinguish between CR4 and STD.
During the DB periods of the study, the number of doses per day was 42% less for CR4 than for STD, 4-14, SEM 0 3 vs 7 14, SEM 0 3 (p < 0-0001). The mean interdose interval was increased 86% from 2-39, SEM O lh on STD to 4 57, SEM 0-2 on CR4 (p < 0 0001). However, the mean daily intake of levodopa was increased 21-8%, from 1128 6, SEM 117 5 to 1371-4, SEM 172-1 mg/day (p < 0 0003). A substantial part of this increase may have been due to the fact that patients were given a bedtime dose of CR4 in hopes of extending benefit into the night. However, only two patients specifically commented on improved sleep patterns or ease of getting out of bed at night, During the DB phase of the study, there was a 28 6% reduction in the number of daily "off " periods, from 2-97, SEM 0-5 on STD to 2-12, SEM 0-3 on CR4 (p < 0-02), and a 11-6% increase in the percent of the waking day spent "on", from 70 12, SEM 5 0 to 78-28, SEM 3 6% (p < 0 02). The percentage of "on" time spent with dyskinesia was unchanged. Again these results were not significantly different from those obtained during the DT periods (table 1 and fig 3) . Curiously, review of patients' diaries from the last 4 weeks of each double blind period did not support patients' observations of an increased "lag time" with CR4. The mean interval recorded from the time of the first dose of medication in the morning to the time when patients first reported being "on" was 0 96, SEM 0 28 (median 0 61) hours on STD and 0 96, SEM 0 19 (median 1 125) hours on CR.
The quantitative improvement in RFs was not, however, accompanied by a qualitative improvement. Except for a slight improvement on "off period selfrating during the open-label portion of the study, mean ADL self-ratings revealed no difference in best "on" performance, worst "off " performance, or in the difference between them (A Off-On) on either the UPDS or the percent scales (table 2) . These selfobservations were confirmed by the lack of significant difference in the mean, range, coefficient of variation (C.V. = Std Dev/Mean), or the area under the disability score-vs-time curve of Parkinson disability (table 3) . However, in contrast to patients' diary reports, an increased "lag time" to the onset of medication effect was reflected by an increase in the interval between the first dose and the first recorded "global" score of 0 or greater, being 0-96, SEM 0-18 (median 0 75) hours on STD and 1-82, SEM 0 33 (median 1-5) hours on CR4. Discussion
The patients completing this double-blind, placebocontrolled, crossover study preferred Sinemet CR4 to STD by a ratio of 3:1. If the patients who dropped out due to excessive dyskinesia or lack of drug effect during the DT phase are included, 58% of the study entrants perceived benefit from CR4 (Chi-square p = 0.04). Patients completing the double-blind portion of the study achieved a slight increase in the amount of daily "on" time when on CR4 as well as a 28-6% reduction in the number of "off" episodes, while taking 42% fewer doses of medication per day than when they were taking STD.
No differences were noted between DT and DB periods for either formulation, and the majority of patients correctly identified the active formulation during the "blinded" periods of the study. This suggests that the blind was, in fact, not adequately maintained owing to the quite distinct temporal pattern of clinical response to CR4 and STD. In fact, complete masking of a study comparing these two formulations may well be impossible for this reason. Nevertheless, the results of this study confirm the results of our previous open-label study with CR42 2' as well as those of Goetz et al. ' 2 Similar results were also obtained by Sage and Mark in a study of similar design to our own.28 These investigators reported an increase of "on" time in 58% of patients, with 79% of patients taking fewer doses per day of CR than of STD, and a reduction in the mean number of doses taken per day from 7-8 of STD to 5 3 of CR4.
Sinemet CR4 behaves more as a slow-release than a truly controlled-release preparation.0 Absorption of levodopa from CR4 does not provide constant plasma levodopa levels throughout the day, but rather allows for an extended interdose interval by prolonging the absorptive phase of the dose cycle. The slower absorption of levodopa from CR4 has two major consequences. The first is an increased lag time to the onset of action ofindividual doses. This was experienced by the patients as a delay to turn "on" in the morning following the first dose of the day, and some patients disliked the absence ofa "surge" ofenergy at the onset of medication, an effect they were accustomed to with STD. The action of successive doses during the day also tended to be less reliable than with STD, and occasional long delays to turn "on", as well as a 211 decreased predictability in the occurrence of "off" periods, were experienced by most patients. The second major consequence of the prolonged absorption of levodopa from CR4 is that successive doses tend to produce successively greater peaks in plasma levodopa levels, since interdose trough levels tend to be higher than those seen with STD. This led to increasing severity of dyskinesia late in the day, which was dealt with by giving larger doses in the morning than in the afternoon. Reducing the size of the afternoon doses often reduced the amount of dyskinesia, but at the price of additional "off " time. In open treatment we have found the addition of STD to CR4, particularly at the first morning dose and as a prn medication during the day,20 21 can effectively compensate for the increased lag time of CR4 and, in fact, the two are best used in combination.
As in the above-mentioned studies,21'23 28 there was no improvement reported by the patients in the quality of their "on" time during CR4 treatment. That the quality of the "on" time experienced was no different from that with STD should not be surprising. Nutt et al have demonstrated a "ceiling" effect in the action of levodopa. That is, that increasing the dose beyond a certain level for a given patient produces increments only in the duration, but not the quality of the antiparkinson effect, whereas the severity of dyskinesia continues to increase. 7 Given the limitations inherent in the pharmacokinetics and pharmacodynamics of levodopa, Sinemet CR4 appears to be a useful addition to our therapeutic armamentarium. In our group of patients with predictable end-of-dose wearing-off of levodopa effect and relatively mild dyskinesia, reduced dosing frequency and the consequent reduction in the number of "off" periods per day were universally cited by all patients and spouses alike as the major benefit of CR4. It is in this type ofpatient that CR4 is likely to find its greatest usefulness. However, patient with more complicated patterns of response fluctuations may benefit as well.-0
